Thromboses/Coagulation
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia (TAK-079-3002)
- Details
ClinicalTrials.gov ID:
NCT06722235
Diagnosis Type:
NA
USOR Number:
- Address
,
P: